Interleukin-17A expression in human synovial mast cells in rheumatoid arthritis and osteoarthritis

Allergology International

Volumn 65, Issue , 2016, Pages S11-S16

  Kan, Jun ichiro ^a   Mishima, Shintaro ^a   Kashiwakura, Jun ichi ^a,b   Sasaki Sakamoto, Tomomi ^a   Seki, Masayuki ^a   Saito, Shu ^a   Ra, Chisei ^a   Tokuhashi, Yasuaki ^a   Okayama, Yoshimichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

Author keywords

Arthritis; Human mast cells; Interleukin 17; Osteoarthritis; Rheumatoid

Indexed keywords

COMPLEMENT COMPONENT C5A; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 33; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; CYTOKINE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAST CELL; OSTEOARTHRITIS; PRIORITY JOURNAL; REPLACEMENT ARTHROPLASTY; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; UPREGULATION; ARTHRITIS, RHEUMATOID; CELL CULTURE; GENETICS; IMMUNOLOGY; METABOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOMARKERS; CELLS, CULTURED; CYTOKINES; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-17; MALE; MAST CELLS; OSTEOARTHRITIS; SYNOVIOCYTES;

EID: 84969174979     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.1016/j.alit.2016.04.007     Document Type: Article

References (18)

1. 1 Furst, D.E., Emery, P., Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology (Oxford) 53 (2014), 1560–1569.
2. 2 Nakae, S., Nambu, A., Sudo, K., Iwakura, Y., Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171 (2003), 6173–6177.
3. 3 Chu, C.Q., Swart, D., Alcorn, D., Tocker, J., Elkon, K.B., Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 56 (2007), 1145–1151.
4. 4 Hirota, K., Yoshitomi, H., Hashimoto, M., Maeda, S., Teradaira, S., Sugimoto, N., et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204 (2007), 2803–2812.
5. 5 Toh, M.L., Kawashima, M., Hot, A., Miossec, P., Miossec, P., Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis 69 (2010), 1562–1567.
6. 6 Shahrara, S., Pickens, S.R., Mandelin, A.M. 2nd, Karpus, W.J., Huang, Q., Kolls, J.K., et al. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 184 (2010), 4479–4487.
7. 7 Moran, E.M., Mullan, R., McCormick, J., Connolly, M., Sullivan, O., Fitzgerald, O., et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther, 11, 2009, R113.
8. 8 Kotake, S., Yago, T., Kawamoto, M., Nanke, Y., Role of osteoclasts and interleukin-17 in the pathogenesis of rheumatoid arthritis: crucial 'human osteoclastology'. J Bone Miner Metab 30 (2012), 125–135.
9. 9 van den Berg, W.B., Miossec, P., IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 5 (2009), 549–553.
10. 10 Metawi, S.A., Abbas, D., Kamal, M.M., Ibrahim, M.K., Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 30 (2011), 1201–1207.
11. 11 Hueber, A.J., Asquith, D.L., Miller, A.M., Reilly, J., Kerr, S., Leipe, J., et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184 (2010), 3336–3340.
12. 12 van Baarsen, L.G., Lebre, M.C., van der Coelen, D., Aarrass, S., Tang, M.W., Ramwadhdoebe, T.H., et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?. Arthritis Res Ther, 16, 2014, 426.
13. 13 Nigrovic, P.A., Lee, D.M., Synovial mast cells: role in acute and chronic arthritis. Immunol Rev 217 (2007), 19–37.
14. 14 Eklund, K.K., Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 217 (2007), 38–52.
15. 15 Kashiwakura, J., Yanagisawa, M., Lee, H., Okamura, Y., Sasaki-Sakamoto, T., Saito, S., et al. Interleukin-33 synergistically enhances immune complex-induced tumor necrosis factor alpha and interleukin-8 production in cultured human synovium-derived mast cells. Int Arch Allergy Immunol 161:Suppl 2 (2013), 32–36.
16. 16 Lee, H., Kashiwakura, J., Matsuda, A., Watanabe, Y., Sakamoto-Sasaki, T., Matsumoto, K., et al. Activation of human synovial mast cells from rheumatoid arthritis or osteoarthritis patients in response to aggregated IgG through Fcgamma receptor I and Fcgamma receptor II. Arthritis Rheum 65 (2013), 109–119.
17. 17 Noordenbos, T., Yeremenko, N., Gofita, I., van de Sande, M., Tak, P.P., Canete, J.D., et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondyloarthritis. Arthritis Rheum 64 (2012), 99–109.
18. 18 Lin, A.M., Rubin, C.J., Khandpur, R., Wang, J.Y., Riblett, M., Yalavarthi, S., et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187 (2011), 490–500.